SCHEMBL26056992

SCHEMBL26056992

CCC(=O)c1ccc(C(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.66
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
CFTR P13569 1/20 0.44
HSP90AB1 P08238 1/20 0.43
USP2 O75604 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLQ O75417 3/20 0.43
HPD P32754 1/20 0.42
MAPT P10636 1/20 0.42
SLC6A9 P48067 2/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
AVPR2 P30518 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28816565 0.89 CES2 (0.51) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5898534 0.86 CES2 (0.66) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL31491270 0.84 CES2 (0.68) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL14054107 0.84 CES2 (0.49) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL8491028 0.83 CES2 (0.62) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24451071 0.83 HSP90AB1 (0.61) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5367756 0.83 CES2 (0.66) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2075208 0.83 GAA (0.54) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2097720 0.83 CES2 (0.66) CES2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5358174 0.83 CES2 (0.66) CES2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731967-B2 Inhibitors of TRIM33 and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731967-B2 Inhibitors of TRIM33 and methods of use TRIM33, TRIM28, TRIM4 CES2 3614/4885KDM4E 1284/4885ALDH1A1 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.